Long-Term Non-Interventional Latanoprost Study

Inclusion Criteria: * Male or female \<18 years of age (neonates must be at least 36 weeks gestational age). * Diagnosis of pediatric glaucoma or elevated intraocular pressure. * Evidence of a personally signed and dated informed consent document indicating that the subject (and/or a legally acceptable representative) has been informed of all pertinent aspects of the study. A signed and dated assent will be required where applicable according to local laws. For treated subjects only: * Continuously treated with latanoprost for at least 1 month within the year prior to the baseline examination. For untreated subjects only: * Continuously treated with latanoprost or other topical prostaglandin analogues for less than one month prior to the baseline examination (based on the best knowledge of treating ophthalmologists), and unlikely to be treated with latanoprost or other topical prostaglandin analogues during the three-year study period; OR * No prior treatment with latanoprost or other topical prostaglandin analogues, and unlikely to be treated with latanoprost or other topical prostaglandin analogues during the three-year study period. Exclusion Criteria: * Unable/unwilling to comply with protocol. * Pregnant or nursing females at baseline. * For treated subjects only: a history of allergy or hypersensitivity to any of the ingredients contained in latanoprost (e.g., hypersensitivity to benzalkonium chloride).